Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to 0.81%.

  • Bioadaptives' Return on Capital Employed rose 6300.0% to 0.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81%, marking a year-over-year increase of 6300.0%. This contributed to the annual value of 0.39% for FY2024, which is 2500.0% up from last year.
  • Latest data reveals that Bioadaptives reported Return on Capital Employed of 0.81% as of Q3 2025, which was up 6300.0% from 0.81% recorded in Q2 2025.
  • In the past 5 years, Bioadaptives' Return on Capital Employed registered a high of 0.81% during Q3 2025, and its lowest value of 0.11% during Q2 2023.
  • Over the past 5 years, Bioadaptives' median Return on Capital Employed value was 0.3% (recorded in 2021), while the average stood at 0.35%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first crashed by -3400bps in 2023, then skyrocketed by 6600bps in 2025.
  • Over the past 5 years, Bioadaptives' Return on Capital Employed (Quarter) stood at 0.59% in 2021, then crashed by -51bps to 0.29% in 2022, then tumbled by -49bps to 0.15% in 2023, then soared by 157bps to 0.38% in 2024, then skyrocketed by 112bps to 0.81% in 2025.
  • Its Return on Capital Employed was 0.81% in Q3 2025, compared to 0.81% in Q2 2025 and 0.54% in Q1 2025.